Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Morphological and functional findings in COVID-19 lung disease as compared to Pneumonia, ARDS, and High-Altitude Pulmonary Edema

Gustavo R. Zubieta-Calleja, Natalia Zubieta-DeUrioste, Felipe de Jesús Montelongo, Manuel Gabriel Romo Sanchez, Aurio Fajardo Campoverdi, Patricia Rieken Macedo Rocco, Denise Battaglini, Lorenzo Ball, Paolo Pelosi

1. Introduction

Coronavirus disease-2019 (COVID-19) may severely affect respiratory function and evolve to life-threatening hypoxia. The clinical experience led to the implementation of standardized protocols assuming similarity to severe acute respiratory syndrome (SARS-CoV-2). Understanding the histopathological and functional patterns is essential to better understand the pathophysiology of COVID-19 and then develop new therapeutic strategies. Epithelial and endothelial cell damage can result from the virus attack, thus leading to immune-mediated response. Pulmonary histopathological findings show the presence of Mallory bodies, alveolar coating cells with nuclear atypia, reactive pneumocytes, reparative fibrosis, intra-alveolar hemorrhage, moderate inflammatory infiltrates, micro-abscesses, microthrombus, hyaline membrane fragments, and emphysema-like lung areas. COVID-19 patients may present different respiratory stages from silent to critical hypoxemia, are associated with the degree of pulmonary parenchymal involvement, thus yielding alteration of ventilation and perfusion relationships. This review aims to: discuss the morphological (histopathological and radiological) and functional findings of COVID-19 compared to acute interstitial pneumonia, acute respiratory distress syndrome (ARDS), and high-altitude pulmonary edema (HAPE), four entities that share common clinical traits, but have peculiar pathophysiological features with potential implications to their clinical management.

---

**Keywords:**
- HAPE
- SARS-CoV-2
- COVID-19
- Lung sequelae
- Viral pneumonia
- ARDS

**Abbreviations:**
- AIP, acute interstitial pneumonia
- ARDS, acute respiratory distress syndrome
- CO₂, carbon dioxide
- COVID-19, coronavirus disease 2019
- CT, computed tomography
- DAD, diffuse alveolar damage
- DO₂, oxygen delivery
- ECCO₂ R, extracorporeal carbon dioxide removal
- ECMO, extracorporeal membrane oxygenation
- FiO₂, fraction of inspired oxygen
- HAPE, high altitude pulmonary edema
- Hb, hemoglobin
- HIF, hypoxia inducible factor
- IIP, idiopathic interstitial pneumonia
- LUS, lung ultrasound
- MODS, multiple organ dysfunction
- PaCO₂, arterial partial pressure of carbon dioxide
- PaO₂, arterial partial pressure of oxygen
- PaO₂/FiO₂, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen
- PEEP, positive end-expiratory pressure
- SARS-CoV-2, severe acute respiratory syndrome coronavirus-2
- SpO₂, peripheral saturation of oxygen
- V/Q, ventilation/ perfusion
- VILI, ventilator-induced lung injury

**E-mail address:** battaglini.denise@gmail.com (D. Battaglini)

https://doi.org/10.1016/j.resp.2022.104000
Received 2 October 2022; Received in revised form 18 November 2022; Accepted 27 November 2022
Available online 29 November 2022
1569-9048/© 2022 Elsevier B.V. All rights reserved.
19. Pneumonia histopathological findings have been reported different from Table Legend: AIP, acute interstitial pneumonia; ARDS, Acute Respiratory Distress Syndrome; COVID-19, Coronavirus disease 2019; HAPE, high-altitude pulmonary edema.

2. Histopathological findings

2.1. Acute interstitial pneumonia

Different microorganisms can cause pneumonia (or pneumonitis), classically defined as an acute disease marked by inflammation of lung tissue accompanied by infiltration of alveoli and often bronchioles with white blood cells (such as neutrophils) and fibrinous exudate (Travis et al., 2013) (Table 1). The most recent anatomopathological classification dates back to 2013, including the broad definition of idiopathic interstitial pneumonia (IIP), incorporating more than 200 acute or chronic lung diseases with various degrees of inflammation and fibrosis (Travis et al., 2013). AIP is characterized by a severe idiopathic interstitial disease that includes the presence of clinical symptoms, bilateral lung infiltrates on radiographs, and the absence of identifiable etiology (Thille et al., 2013; Travis et al., 2013). In AIP, type I and I epithelial cells may present necrosis, erosion, fibrin exudation and ubiquitin-positive intracytoplasmic inclusion bodies (Mallory bodies) that are ubiquitously present. AIP may evolve to ARDS and fibrosis (Thille et al., 2013).

2.2. ARDS

Diffuse alveolar damage (DAD) is considered the histological hallmark for the acute phase of ARDS (Table 1). DAD can present as typical histologic evolution of AIP, but the clinical evolution of AIP and DAD are different. Indeed, AIP and DAD constitute two independent entities that often coexist (Cardinal-Fernández et al., 2017). Three phases of traditional ARDS have been identified: 1) acute phase (<48 h) with interstitial and alveolar edema, 2) subacute phase (days 3–7) with the formation of hyaline membranes and fibrin deposits, and 3) proliferative phase (>7 days) with abundant fibroblast in the interstitium, fibrosis, and hyperplasia of type II pneumocytes (Mukhopadhyay and Parambil, 2012). Hyaline membrane formation and DAD with fibrin exudation and intraluminal granulation can be maintained due to epithelial cell damage (Guerin et al., 2015). Lung histopathology differs in pulmonary and “extrapulmonary” ARDS (Pelosi et al., 2003), although both are characterized by increased lung weight compared to normal lungs (1.700–2.500 g vs 800 g, respectively) and presence of DAD, albeit with different distribution. Pulmonary ARDS primarily affects the alveolar epithelium, with damage occurring mainly in the intra-alveolar space, with alveolar flooding and areas of consolidation (Menezes et al., 2005; Rocco and Pelosi, 2008). In extrapulmonary ARDS, vascular endothelial cells are the first target of damage, with a subsequent increase in vascular permeability. The main pathologic alteration due to an indirect insult may be micro-vessel congestion and interstitial edema, with relative sparing of intra-alveolar spaces. The histopathological distinction between “pulmonary” and “extrapulmonary” ARDS has not been always feasible due to the frequent overlapping of these two clinical situations (Gattinoni et al., 2001; Goodman et al., 1999). DAD might evolve to fibrosis regardless of the underlying lung condition; however, its frequency, specific findings and pathogenesis might be disease-specific (Ackermann et al., 2020; Ball et al., 2021a; Kemp et al., 2022).

2.3. High altitude pulmonary edema

HAPE is a non-cardiogenic pulmonary edema that develops after exposure to high altitudes (> 1700 – 2000 m above sea level) (Giesenhanen et al., 2019). It is assumed that there exists a genetic predisposition to HAPE and this might be associated with an exaggerated vascular response in patients susceptible to hypoxia and poor outcome in those with COVID-19 (Garrido et al., 2022). Histological findings of HAPE include marked diffused alveolar edema, congested pulmonary arterioles and capillaries, and occasional alveolar hyaline membranes (Droma et al., 2001) (Table 1). In most severe cases, histological findings may be compatible with DAD. In particular, the alveolar spaces are often distended with edema extended to alveoli, alveolar ducts, sacs, and respiratory bronchioles. The edema includes red blood cells, polymorphonuclear cells, and macrophages. Additionally, alveolar capillaries and pulmonary arterioles are congested with stasis. Intra-alveolar hemorrhage can be present in scattered areas of lung parenchyma in the more severe cases. Thrombi and fibrin clots plugging arterioles and pulmonary arterioles are associated with vascular congestion and edema.

Table 1

| Disease   | Anatomopathological findings                                                                                     |
|-----------|-------------------------------------------------------------------------------------------------------------------|
| AIP       | Lung tissue derangement with alveolar collapse. Hydroaline membrane formation. Polymorphonuclear and monocytes infiltration. Pneumocytes in type 2 are damaged and lead to interstitial edema. Reactive pneumocytes with nuclear atypia and hyperplasia. Mallory-like inclusions in type 2 pneumocytes. Early fibroblastic interstitial fibrosis. Septal and para-septal reparative fibrosis. |
| ARDS      | Lung tissue derangement with alveolar collapse. Intra-alveolar and interstitial edema. Necrotic alveolar epithelial cells and exudates of serum proteins from the damaged and leaky capillaries. Alveolar type I cell necrosis, alveolar type II cell proliferation, interstitial proliferation of fibroblast and myofibroblast or organizing interstitial fibrosis. Hyaline tissue formation. Reactive pneumocytes with nuclear atypia and hyperplasia. Mallory-like inclusions in type 2 pneumocytes. Scattered neutrophilic infiltrates localized to terminal bronchioles and surrounding alveoli with evident confluent of infiltrates between adjacent lobules. Thrombi are common in small/medium pulmonary arterioles. Abundant fibroblast in the interstitium, fibrosis and interstitial thickening by fibroblasts. |
| HAPE      | Diffuse alveolar edema including red blood cells, polymorphonuclear cells, and macrophages. Widened septa due to interstitial edema. Occasional alveolar hyaline membranes. Type II pneumocytes could be damaged (due to stress failure) and pulmonary surfactant impaired. Congested pulmonary arterioles and capillaries. Intra-alveolar hemorrhage is present in scattered areas of lung parenchyma, particularly in the more severe cases. Thrombi and fibrin clots plugging arterioles and capillaries. |
| COVID-19  | Lung tissue derangement with alveolar collapse. Intra-alveolar hemorrhage. Alveolar rupture. Hyaline tissue formation. Polymorphonuclear and monocytes infiltration. Active viral replication within type 2 pneumocytes. Reactive pneumocytes with nuclear atypia and hyperplasia. Mallory-like intracytoplasmic inclusions in type 2 pneumocytes. Mason’s bodies. Microthrombi, vasculitis or vascular thrombosis. Early fibroblastic interstitial fibrosis, septal and para-septal reparative fibrosis. |

Table Legend: AIP, acute interstitial pneumonia; ARDS, Acute Respiratory Distress Syndrome; COVID-19, Coronavirus disease 2019; HAPE, high-altitude pulmonary edema.
capillaries can occasionally be found. The alveolar structures are usually maintained, but the septa are widened due to interstitial edema, while hyaline membranes can be eventually observed (Droma et al., 2001). HAPe is clearly associated with pulmonary artery hypertension, which manifests with changes in the pulmonary vascular endothelium characterized by 1) a transition form, from a quiescent state to an activated state with acquisition of adhesive capacity, 2) an aberrant proliferative and apoptosis-resistant phenotype, 3) a pro-inflammatory phenotype with the release of cytokines and chemokines, and 4) a fibrotic phenotype with the release of growth factors, angiogenesis, and leukin (Huertas et al., 2018). Type II epithelial cells could be damaged and pulmonary surfactant impaired (Droma et al., 2001). Nevertheless, these lung histological changes reverse within 24 h in younger patients and up to several days in older patients, never resulting in fibrosis.

2.4. COVID-19 pneumonia

Lung histopathology in COVID-19 pneumonia (Edler et al., 2020; Hanley et al., 2020; Pomara et al., 2020) is characterized by an inflammatory process (neutrophil and mononuclear cell infiltration), alveolar destruction and collapse, hyaline tissue formation, microhemorrhage and micro-lobes possibly due to superinfection, which can result in extensive disruption of the lung parenchyma (Zubieta-Calleja and Zubieta-DeUrioste, 2021b). Pathological findings in the cells include intra-alveolar Masson Bodies, which are a typical hallmark of organizing pneumonia. Nuclear atypia of epithelial cells is also present (Zubieta-Calleja and Zubieta-DeUrioste, 2021b) (Table 1). Severe COVID-19 pneumonia shares some pathological similarities with “pulmonary” ARDS characterized by lung inflammation, presence of consolidation, some areas of atelectasis, changes in vascular permeability, and hypoxemia (Ackermann et al., 2020; Ranieri et al., 2012). Autopsy findings in severe COVID-19 pneumonia patients reveals the presence of DAD, fibrosis, bullae-filled necrotic lung tissue, chronic lung inflammation, edema in the bronchial mucosa, and thromboembolic events (Barisone et al., 2021; Barton et al., 2020; Edler et al., 2020; Wichmann et al., 2020). Three phases, similar to the traditional DAD, have been identified: 1) the acute/early exudative phase that is characterized by intra-alveolar edema and interstitial widening, with a peak of hyaline membrane (both diffuse and focal) formation 4–5 days after initial insult (Angeles Montero-Fernandez and Pardo-Garcia, 2021); 2) an organizing/mid proliferative phase, which is characterized by cellular fibroelastic proliferation, type II epithelial cell hyperplasia, and squamous metaplasia; and 3) late/fibrous phase DAD with honeycombing (Barisone et al., 2020). The hyaline membranes are in this stage fused into the alveolar septa and not easily recognizable (Angeles Montero-Fernandez and Pardo-Garcia, 2021). Post-mortem transcortical lung cryobiopsies during mechanical ventilation confirmed the presence of “pneumocyte loss” (pneumolysis) with discontinuation of the alveolar epithelial lining, hyaline membranes, intra-alveolar fibrinous exudate, early interstitial fibrosis, obliteration of the alveolar structure by fibrosis, type 2 epithelial cell hyperplasia and atypia, Mallory-like intracytoplasmic inclusions in type 2 epithelial cells, micro-honeycombing, foci of bronchopneumonia, associated with vascular lysis, vasculitis or vascular thrombosis (Barisone et al., 2020). Vascular microthrombosis was described in conventional ARDS but occurs more frequently in COVID-19 (Ackermann et al., 2020).

2.4.1. Parenchymal destruction in severe COVID-19 pneumonia

Parenchymal destruction is the most severe evolution of COVID-19 pneumonia (Zubieta-Calleja and Zubieta-DeUrioste, 2021b). Irreversible remodeling of lung parenchyma, with fibrotic tissue adhering to the parietal pleura, was firstly described in pulmonary tuberculosis (Hall, 1938). It was therefore observed in COVID-19, in the context of a disease evolving to progressive hypoxemia, subsequent hypcapnia, and altered shunt (Zubieta-Calleja et al., 2021). A gel-like fluid has been found in autopsy lung samples in COVID-19, and the presence of hyaluronan has been reported (Hellman et al., 2020). COVID-19 patients present initially a predominance of advanced lesions in the lower lobes of both lungs. The probable explanation could be associated with aerodynamics and lung elasticity that initially respond with lower lobes distention on inhalation due to diaphragmatic contraction and direct main bronchi orientation, driving the SARS-CoV-2 directly to impact the lungs in that area (Yan et al., 2020). These findings in COVID-19 differentiate itself from HAPe, which occurs on a rapid ascent to high altitude in some individuals who can present an arterial partial pressure of oxygen (PaO_{2}) as low as 30 mmHg but can fully recover within a few days. Also, in COVID-19, there is lung pneumocyte destruction followed by inflammation. HAPe-like edema, and some minor hemorrhage, giving rise to severe lung damage. However, HAPe-like edema in COVID-19 could be concomitantly present since the exclusion and destruction of respiratory units reduces the gas exchange surface significantly, simulating a high-altitude abrupt ascent. The normal remaining lung tissue can suffer edema as it results from extreme hypoxia, pulmonary hyppertension, and stress failure of capillaries. The brownish color of the lungs probably results from the iron deposit due to hemolysis in the interstitium where fibrosis is forming.

3. Radiological findings

3.1. Acute interstitial pneumonia

Chest radiograph in AIP shows bilateral opacifications with air bronchograms and sparing of the costophrenic angles. Consolidation can appear during the organizing phase with a possible ground glass appearance and irregular lung opacities (Primack et al., 1993). Chest computed tomography (CT) findings of AIP patients reveal ground glass attenuation areas with a mosaic pattern and air space consolidation in dependent areas. This pattern results from alveolar septal edema, and hyaline membrane formation at histology, which are typical of the exudative phase (Palmucci et al., 2014). These signs are commonly bilateral, sometimes diffuse or localized to the upper lobes. Intra-alveolar fibrosis with consolidation can be identified in the organizing phase with possible bronchiectasis formation and cyst. The latter are more common in the non-dependent lung areas (Palmucci et al., 2014) (Table 2).

3.2. ARDS

Studies have described morphological differences at chest CT scan in patients with pulmonary and extrapulmonary ARDS (Gattinoni et al., 2001; Goodman et al., 1999). “Pulmonary” ARDS appears to be asymmetric, with a mix of consolidation and ground-glass opacification, while “extrapulmonary” ARDS presents a symmetric ground-glass opacification. However, to date there has been no tomographic characteristic able to predict the etiology of ARDS (Desai et al., 1999), since direct and indirect injuries can coexist, making interpretation of the morphological pattern more difficult. In the organizing and fibrotic phase, traction bronchiectasis and reticulation may develop with an anterior predominance (Obadina et al., 2013) (Table 2). Typical patterns at CT scan in “pulmonary” and “secondary” ARDS are shown in Fig. 1.

3.3. High altitude pulmonary edema

Chest radiograph of patients with HAPe presents distinct patterns which can often be confused with cardiopulmonary diseases (Nair et al., 2021). Unilateral or bilateral asymmetrical alveolar-interstitial opacities with relative sparing of the periphery and apices have been identified in some patients (Zubieta-Calleja and Zubieta-DeUrioste, 2021a). The opacities could be marginated, and the distribution patchy, with initial confluence in the perihilar region, and prominent horizontal fissure. Other images showed lobar consolidation, limited by a horizontal fissure. Focal patchy air-space opacities/ consolidations, thus mimicking.
or diffuse opacities were noted in some cases, although a monolateral pulmonary edema. Distress Syndrome; COVID-19, Coronavirus disease 2019. HAPE, high-altitude

### Table Legend
- **AIP**: acute interstitial pneumonia; **ARDS**: Acute Respiratory Distress Syndrome; **COVID-19**: Coronavirus disease 2019; **HAP**: high-altitude pulmonary edema.

| Disease | Radiological findings |
|---------|-----------------------|
| **AIP** | Ground grass attenuation areas with a mosaic pattern and air space consolidation in dependent areas, bibasilar, diffuse or localized in the upper lobes. Intra-alveolar fibrosis with consolidation in the organizing phase with possible bronchiectasis formation and cyst, especially in the non-dependent lung areas. In “pulmonary” ARDS appearance is asymmetric, with a mix of consolidation and ground-glass opacification, possible pleural effusion, and emphysema. Predominance of air bronchograms and pneumomediastinum. In “extrapulmonary” ARDS predominantly symmetric ground-glass opacification are present with possible pleural effusion and emphysema. Ground-glass opacification and consolidation are greater in the central third of the lung than in the sternal or vertebral third without significant cranio-caudal predominance. Consolidation is mainly distributed in the middle and basal levels as well as the vertebral position. | **ARDS** | Heterogeneous foci of consolidation, ground-glass opacities (with gravitational gradient), and crazy paving, with predominance in the posterior and basal areas. Possible air bronchograms and small pleural effusions. In the organizing and fibrotic phase, traction bronchiectasis and reticulation may develop (anterior predominance). |
| **HAPE** | Unilateral or Bilateral asymmetrical alveolo-interstitial opacities with relative sparing of the periphery and apices, usually margined, with patchy distribution and initial confluence in the perihilar region, and prominent horizontal fissure, interfaced with normally aerated areas. Possible lobar consolidation limited by horizontal fissure. Focal patchy air-space opacities/ consolidations. Pulmonary edema usually occurs in areas of high blood flow, with a patchy distribution. | **COVID-19** | Phenotype 1 (or L) usually presents as multiple focal over perfused ground glass opacities and normally aerated areas and is prevalent of mild to moderate diseases. Possible diversion of ventilation toward non-dependent aerated lung regions and reduction in pulmonary perfusion due to increased airway pressure, collapse of capillaries and/or microthrombosis and formation of no recruitable atelectasis. Phenotype 2 (or H) shows a patchy ARDS-like pattern, with inhomogeneously distributed and hyper/hypo-perfused areas that is associated with severe disease (Gattinoni et al., 2020; Robba et al., 2020a) that presents as multiple focal over perfused ground glass opacities receiving more perfusion than ventilation and normally aerated areas, and is prevalent of mild to moderate diseases. In this case, possible diversion of ventilation toward non-dependent aerated lung regions and reduction in pulmonary perfusion due to increased airway pressure, the collapse of capillaries and/or micro-thrombosis and formation of non-recruitable consolidation can appear; 2) a phenotype 2 (or H) (Gattinoni et al., 2020; Robba et al., 2020a) that shows a patchy ARDS-like pattern, with inhomogeneously distributed and hyper/hypo-perfused areas that are associated with severe disease (Gattinoni et al., 2020; Orlandi et al., 2021). In this case, the lung weight can be increased with consolidated and non-aerated lung regions mainly distributed in the dependent lung regions. Areas with low ventilation/perfusion (V/Q) persist, but are associated with “true shunt” areas; 3) A phenotype (F) which represents a final evolution to fibrosis (Gattinoni et al., 2020; Robba et al., 2020a; Tonelli et al., 2021). The incidence rate of each COVID-19 phenotype was 62% and 10% for 1 and 2 phenotypes, respectively, in severe COVID-19 patients. Chest CT and lung ultrasound imaging (LUS) differed between survivors (mostly phenotype 1) and non-survivors (mostly phenotype 2) and were associated with ICU mortality (Orlandi et al., 2021). Moreover, chest CT positively correlates with lung ultrasound findings suggesting that it can be a valuable monitoring tool in critically ill settings for daily monitoring (Orlandi et al., 2021) (Table 2). Fig. 3 presents typical patterns of COVID-19 phenotype 1 and phenotype 2 at CT scan. |

### 3.4. COVID-19 pneumonia

Distinct COVID-19 pneumonia phenotypes have been identified in the chest CT, including 1) a phenotype 1 (or L) (Gattinoni et al., 2020; Robba et al., 2020a) that presents as multiple focal over perfused ground glass opacities receiving more perfusion than ventilation and normally aerated areas, and is prevalent of mild to moderate diseases. In this case, possible diversion of ventilation toward non-dependent aerated lung regions and reduction in pulmonary perfusion due to increased airway pressure, the collapse of capillaries and/or micro-thrombosis and formation of non-recruitable consolidation can appear; 2) a phenotype 2 (or H) (Gattinoni et al., 2020; Robba et al., 2020a) that shows a patchy ARDS-like pattern, with inhomogeneously distributed and hyper/hypo-perfused areas that are associated with severe disease (Gattinoni et al., 2020; Orlandi et al., 2021). In this case, the lung weight can be increased with consolidated and non-aerated lung regions mainly distributed in the dependent lung regions. Areas with low ventilation/perfusion (V/Q) persist, but are associated with “true shunt” areas; 3) A phenotype (F) which represents a final evolution to fibrosis (Gattinoni et al., 2020; Robba et al., 2020a; Tonelli et al., 2021). The incidence rate of each COVID-19 phenotype was 62% and 10% for 1 and 2 phenotypes, respectively, in severe COVID-19 patients. Chest CT and lung ultrasound imaging (LUS) differed between survivors (mostly phenotype 1) and non-survivors (mostly phenotype 2) and were associated with ICU mortality (Orlandi et al., 2021). Moreover, chest CT positively correlates with lung ultrasound findings suggesting that it can be a valuable monitoring tool in critically ill settings for daily monitoring (Orlandi et al., 2021) (Table 2). Fig. 3 presents typical patterns of COVID-19 phenotype 1 and phenotype 2 at CT scan.

### 4. Gas-exchange: general principles

AIP, ARDS, HAPE, and COVID-19 pneumonia present similar symptoms. However, a careful evaluation could identify some minimal or marked differences in the diagnostic criteria, definition, gas-exchange abnormalities, and clinical manifestations. In normal lung, gas-exchange is determined by the greater amount of normally aerated and perfused alveoli, with low venous admixture and wasted ventilation. Matching between ventilation (V) and perfusion (Q) of lung regions is the main determinant of gas-exchange (Petersson and Glenny, 2014). Venous admixture, mainly impairing oxygenation, is determined by lung areas with lower V/Q ratios and/or true shunt (Petersson and Glenny, 2014). In normal lungs, a continuous distribution of alveoli from lower (0.001) to higher (10) V/Q areas are present following a gaussian shape, while it may present skewness in pathological conditions. In normal lungs, lung areas with extremely low V/Q are less frequent, while those with V/Q between 1 and 0.1 are predominant. On the other hand, lung areas of “true shunt” are minimal and mostly due to anatomical shunt (3–5%). This means that in normal conditions, breathing in air, the oxygen content and arterial partial pressure of...
oxygen (PaO$_2$) are only slightly lower than alveolar PO$_2$ (PAO$_2$) leading to low PAO$_2$-PaO$_2$ difference (Petersson and Glenny, 2014). In pathological conditions, when lung areas present extremely low V'/Q' ratios, the oxygen content, as well as PaO$_2$ decrease, while the PAO$_2$-PaO$_2$ difference increases (Fajardo et al., 2020). Thus, administering higher inspiratory oxygen fractions, in the presence of increased venous oxygen content, as well as PaO$_2$ decrease, while the PAO$_2$-PaO$_2$ difference increases (Fajardo et al., 2020). Thus, administering higher inspiratory oxygen fractions, in the presence of increased venous...
admixtire mainly due to lower V'/Q', the oxygen content and PaO₂ increase while the PAO₂-PaO₂ difference decreases. This is explained by the fact that alveoli with low V'/Q' areas are open to inspiratory gases and may be reached by increased FiO₂ (Petterson and Glenny, 2014). On the other hand, in pathological conditions, when extremely high "true shunt" predominated, while breathing ambient air, the oxygen content as well as PaO₂ decrease while the PAO₂-PaO₂ increases similarly or even greater compared to low V'/Q'. However, administering higher inspiratory oxygen fractions in the presence of increased venous admixture mainly due to higher "true shunt", the oxygen content, as well as PaO₂, minimally increase while the PAO₂-PaO₂ gradient minimally decreases (Karbıng et al., 2020) (Fig. 4). This is explained by the fact that in the presence of increased venous admixture mainly is due to increased "true" shunt, although some alveoli may contain a high fraction of inspired oxygen (FiO₂), but the oxygen within them cannot diffuse into the capillaries that are closed (shunt) (Fig. 4). Wasted ventilation is due to high V'/Q' areas as well as increased dead space (areas ventilated but not perfused), resulting predominantly in impairment of CO₂ removal. In these lung regions, alveolar oxygenation depends on inspired oxygen fraction, but the effectiveness of carbon dioxide (CO₂) washout is impaired by lower (high V'/Q') or absent (dead space) perfusion. These areas represent part of the lung that do not contribute to increased oxygen content or PaO₂ while impairing CO₂ washout yield increased inspiratory wasted effort (Karbing et al., 2020). A high PaCO₂ reduces the hypoxia tolerance, further aggravating the deleterious effects of hypoxia (Zubieta-Calleja et al., 2013). Fig. 5 depicts the response of V'/Q' to increased FiO₂, while Fig. 6 depicts possible V'/Q' distribution in different pathological conditions.

4.1. Acute interstitial pneumonia

In AIP, hypoxemia is mainly associated with increased lung weight, lung consolidation, and increased intrapulmonary shunt. Consolidation may be localized or widely distributed along the ventral-dorsal gradient or in the dependent lung regions in the supine position. On the other hand, the perfusion is mainly gravity-dependent (similar to ARDS), yielding increased venous admixture due to true shunt (Dakin et al., 2011). The lung areas of low V'/Q' are present but not markedly affecting gas-exchange impairment. On the other hand, increased wasted ventilation due to the combination of high alveolar dead space and high V'/Q' may be present mainly due to diversion of ventilation toward non-dependent aerated lung regions and reduction in pulmonary perfusion due to increased airway pressure or micro-thrombosis. V'/Q' ratio in patients with interstitial pneumonia was firstly described many years ago. V'/Q' profile in sub-pleural lung zones with high V'/Q' ratios and dead space (wasted ventilation) showed flattened peaks with broadened V'/Q' distribution (Suga et al., 2009) (Fig. 6).

4.2. ARDS

In ARDS, higher regional perfusion and true shunt are in the dependent lung regions [11] and edema follows a ventral-dorsal gradient [12] with prevalent low V'/Q' and shunt (Fig. 6). The pressure applied on dependent lung regions favors progressive atelectasis formation (Pelosi et al., 1994), while positive end-expiratory pressure (PEEP) keeps the dependent alveoli open, improving gas-exchange and respiratory system compliance (Gattinoni et al., 1994). Hypoxemia is mainly associated with increased lung weight and atelectasis, yielding increased intrapulmonary shunt. Atelectasis is localized in the dependent lung regions in the supine position. In this clinical condition, the perfusion is mainly gravity-dependent, and the venous admixture is primarily due to true shunt (Dakin et al., 2011). In pulmonary ARDS, there are some lung regions with lower V'/Q', which do not markedly affect gas-exchange. Moreover, there are areas of increased dead space.

4.3. High altitude pulmonary edema

The pathophysiology of HAPE involves a reduced environmental partial pressure of inspired oxygen causing hypoxic pulmonary vaso-constriction that leads to an increased pulmonary arterial pressure with focalized higher pulmonary vascular resistances, higher heart rate and lower arterial oxygen saturation (Chanana et al., 2020). The etiopathology of HAPE is not clear and several hypothesis have been described: 1) genetic predisposition; 2) changes in renin-angiotensin-aldosterone system (RAS), since aldosterone increases the retention of extracellular fluid (Chanana et al., 2020); 3) modifications in nitric oxide (NO), which usually maintains the pulmonary vascular homeostasis; 4) different expression of hypoxia-inducible factor (HIF) – 1 that exponentially increases when the cellular oxygen is low (Chanana et al., 2020); 5) viral infection which may explain the similar pattern observed in COVID-19 pneumonia (Zubieta-Calleja, 1989). The tongue in HAPE has very similar characteristics to the tongue in COVID-19. Clinical symptoms of HAPE include dyspnea, frothy pink sputum, tachypnea, persistent cough, cyanosis, and tachycardia (Chanana et al., 2020). The

Fig. 5. Changes in gas exchange according to ventilation perfusion after increasing FiO₂. This figure depicts changes in gas exchange according to ventilation (V')/perfusion (Q') alterations after increasing the fraction of inspired oxygen (FiO₂). Above, venous admixture with three possible conditions: 1) low V'/Q' with normal alveolar ventilation and increased capillary perfusion that rising FiO₂ will determine marked increase of PaO₂ and PpO₂; 2) low V'/Q' with decreased alveolar ventilation and normal capillary perfusion that rising FiO₂ will determine increase of PaO₂ and marked increase of PpO₂ and 3) true shunt with absent alveolar ventilation and variable capillary perfusion not modified by FiO₂. Below, wasted ventilation with three possible conditions: 1) high V'/Q' with normal alveolar ventilation and decreased capillary perfusion that rising FiO₂ will determine marked increase of PaO₂; 2) high V'/Q' with normal capillary perfusion that rising FiO₂ will determine marked increase of PpO₂ and 3) dead space with normal alveolar ventilation but absent capillary perfusion that with FiO₂ will not change.
clinical diagnosis of HAPE is based on the presence of breathlessness, cough, chest discomfort and headache along with tachycardia, tachypnea, and a SpO<sub>2</sub> < 86% for an altitude of 3500 m in a patient arriving to high altitude within up to 5 days. (Chawla and Tripathi, 2015). Regarding gas exchange and ventilation distribution, HAPE presents mainly wasted ventilation and less low V/Q and high true shunt due to alveolar collapse (Fig. 6).

4.4. COVID-19 pneumonia

Patients with COVID-19 pneumonia may present “silent hypoxemia” or “asymptomatic hypoxemia” with a peripheral saturation of oxygen (SpO<sub>2</sub> < 95% at sea level) accompanied by shortness of breath upon mild exercise, fever, tachycardia, tachypnea, hyperventilation, with intercostal and diaphragmatic fatigue, the sensation of drowning, gasping and subsequent death. SARS-CoV-2 infection affects not only the lung (Zubieta-Calleja et al., 2021) but also other organs (Robba et al., 2020b). Clinical diagnosis is based on the presence of SpO<sub>2</sub> < 90% (PaO<sub>2</sub> < 60 mmHg) at sea level and lower as altitude increases. In COVID-19, gas exchange is determined by the evolutive stages of the disease. In phenotype 1, lung weight is minimally increased compared to normal lungs (1.100 gr vs 800 gr, respectively), and hypoxemia is mainly associated with increased ground-glass regions and low V/Q areas are inhomogeneously distributed within the lung parenchyma. Low V/Q areas might be associated with lower ventilation and possibly some degree of hypoxic vasoconstriction and/or greater perfusion in normally and/or poorly aerated areas. The areas of low V'/Q' are markedly increased all over the lung from ventral to dorsal and from cranial to caudal lung regions (Pelosi et al., 1994) (Fig. 6). A possible explanation could be a decreased ventilatory drive, that may contribute to the silent hypoxemia. On the other hand, increased wasted ventilation due to the combination of high alveolar dead space and low V'/Q' is present in up to 40–50% of the total lung tissue mass, mainly due to diversion of ventilation toward non-dependent aerated lung regions and reduction in pulmonary perfusion due to increased airway pressure, collapse of capillaries and/or micro-thrombosis and formation of no recruitable atelectasis (Pelosi et al., 1994). This can also be justified by the increase in mucinous filling and pulmonary and vascular alterations (Ball et al., 2021c). In phenotype 2, lung weight is markedly increased (1600 – 1700 gr), and hypoxemia is mainly associated with increased consolidated and non-aerated lung regions mainly distributed in the dependent lung regions. Under these clinical conditions, areas with low V'/Q' persist but also combined with areas of “true shunt”. On the other hand, the amount of increased wasted ventilation is high and comparable with what is observed in phenotype 1 (L) (Fig. 6).

5. Intensive care management

All these four pathophysiological entities present similar but also peculiar characteristics of treatment. There is not specific treatment for AIP and ARDS being the management of these two conditions is mainly supportive (Tasaka et al., 2022; Xaubet et al., 2013). In AIP and ARDS of infective etiology, broad-spectrum antibiotics are recommended initially until infectious etiology is confirmed, thereby selecting narrower spectrum antibiotics. No clear benefit of corticosteroids has been confirmed in both AIP and ARDS (Chang et al., 2022). However, recent data suggest potential benefits of dexamethasone (Villar et al., 2020) or methylprednisolone and hydrocortisone in patients with ARDS (Chang et al., 2022). Further trials are warranted to confirm their efficacy. Supportive therapies for AIP are like those applied for ARDS, using a stepwise approach to increase the complexity of treatment according to the increased severity of lung disease. In mechanically ventilated subjects, a lung protective ventilator strategy should be adopted (Tasaka et al., 2022; Xaubet et al., 2013). In HAPE, the first-line treatment is the administration of oxygen and the rapid descent to lower altitudes. Medical therapy includes nifedine, whereas a phosphodiesterase type 5 inhibitor may be helpful but is not formally included in guidelines. Diuretics are not recommended (Wilkins et al., 2015). Treatment possibilities of COVID-19 pneumonia should consider both
anatomopathological and clinical findings. The separation in different phenotypes according to respiratory compliance has been recently challenged, concluding that no change in conventional lung-protective ventilation strategies is warranted (Reddy et al., 2022). We interpreted different phenotypes as an evolution and progression of the disease and lung injury and not as separate entities. In case of “silent hypoxemia”, in which the degree of hypoxemia may not correspond to the severity of lung images and histopathological findings, early therapy may include the use of high-flow nasal oxygen or continuous positive end-expiratory pressure (CPAP) (Robbia et al., 2021a). Noninvasive respiratory support can be considered as the first step toward COVID-19 management in phenotype 1, while early intubation and invasive mechanical ventilation should be considered for phenotype 2 or worsening of phenotype 1. A recent meta-analysis concluded that the timing of intubation may have no effect on mortality and morbidity in critically ill COVID-19 (Papoutsis et al., 2021). During invasive mechanical ventilation, COVID-19 patients showed a decrease in pulmonary and gas volume and increased regions of poorly aerated and non-aerated lung tissue more than patients treated with non-invasive respiratory support (Ball et al., 2021b). In COVID-19 phenotype 1 (U), a relatively preserved lung compliance is present with few areas that can be recruited and low V‘/Q’ areas. In this case, using a moderate PEEP level to redistribute pulmonary blood flow from non-ventilated to more ventilated areas could be suggested. Phenotype 2 (H) might benefit from invasive mechanical ventilation when non-invasive respiratory treatment is not effective, with progressive oxygen deterioration, prompt intubation is required. The respiratory treatment suggested is like that reported in “primary” ARDS with protective ventilation and moderate levels of PEEP individualized on patients’ need, with cautious use of recruitment maneuvers. Prone position may be effective to improve oxygenation, but improvement in oxygenation is often associated with redistribution of perfusion and not effective alveolar recruitment (Rossi et al., 2021). Indeed, when the ventilation of dependent areas is impaired in the supine position, prone rescue positioning can be applied. The gravitational effect makes the ventilation of dependent areas more prone position allows a more homogeneous distribution of ventilation and perfusion, reducing the risk of ventilator-induced lung injury (VILI), but improvement in oxygenation is often associated with redistribution of perfusion and not effective alveolar recruitment in COVID-19 (Battaglini et al., 2021; Rossi et al., 2021). The amount of consolidated tissue was higher in patients assessed with progressive oxygen deterioration, prompt intubation is required. The respiratory treatment suggested is like that reported in “primary” ARDS with protective ventilation and moderate levels of PEEP individualized on patients’ need, with cautious use of recruitment maneuvers. Prone position may be effective to improve oxygenation, but improvement in oxygenation is often associated with redistribution of perfusion and not effective alveolar recruitment in COVID-19 (Battaglini et al., 2021; Rossi et al., 2021). The amount of consolidated tissue was higher in patients assessed during the third week and determined the oxygenation responses following pronation and recruitment maneuvers. In most refractory and severe cases, extracorporeal carbon dioxide removal (ECCO2R) and extracorporeal membrane oxygenation (ECMO) could be used in order to reduce Plateau pressures and tidal volumes and prevent VILI while adequately oxygenating the lungs and improving oxygen supply to all tissues (Battaglini et al., 2021). Other treatment options for improving gas exchange, include the use of erythropoietin in the treatment of severe COVID-19 pneumonia (Ehrenreich et al., 2020; Soliz et al., 2020) which can help improve the oxygen transport to tissues of the compromised oxygen transport triad (pneumodynamic pump, hemodynamic pump, and hemoglobin) (Zubieta-Callega et al., 2021; Zubieta-Callega and Zubieta-DeUrioste, 2021a). Erythropoietin could also exert indirect effects not limited to the increase of red blood cells, hematocrit and hemoglobin but also to the protective effects of the hormone in different tissues like the heart, the vessels, and the brain (Ehrenreich et al., 2020; Hadadi et al., 2020; Sabine-Naehaj et al., 2020). In fact, an association between acute lung injury and brain hypoxia has been described (Battaglini et al., 2020a). Hence, reduced systemic oxygenation can be associated with reduced brain tissue oxygenation and poor outcome (Battaglini et al., 2020a). Furthermore, the increase of hemoglobin becomes a fundamental factor of hypoxia tolerance, as previously shown by the Formula of Tolerance to hypoxia = Hb/PaCO₂ * 3.01 (Hb, hemoglobin; PaCO₂, arterial partial pressure of CO₂). This formula states that higher hemoglobin and a lower PaCO₂ give greater tolerance to hypoxia (Zubieta-Callega et al., 2013). Indeed, PaO₂ and oxygen delivery (DO₂) can be optimized by modulating Hb concentration, pH, PaCO₂, cardiac output, and arterial content of oxygen. Thus, increasing hemoglobin and cardiac output could be considered in this specific clinical setting in order to improve oxygen delivery (Battaglini et al., 2020a). In addition to these parameters, others should be considered when facing hypoxia at high altitude. According to the alveolar gas equation, the alveolar partial pressure of oxygen is dramatically decreased at high altitude, but a higher diffusion capacity is presumed, with a supposed physiological adaptation to altitude (Zubieta-Callega et al., 2013). Some literature suggests that physiological adaptation to altitude may counterbalance the hypoxic environment thus protecting from severe SARS-CoV-2 infection, probably mediated by reduced survival of the virus at high altitude, and down-regulation of ACE2 (Arias-Reyes et al., 2020). Modulation of the inflammatory response is a matter of debate in both ARDS and COVID-19 (Chaudhari et al., 2021). COVID-19 can trigger a “cytokines storm” in lung tissues and systemic circulation with the hyperactivation of the inflammatory-immune system. The accumulation of immune cells at infected sites can result in ARDS. Accordingly, a “cytokines storm” has been previously described in several conditions, including AIP and ARDS (Sinha et al., 2020). In HAPE, hyper-inflammatory status has been attributed to the formation of pulmonary edema. The possible implication for treatment could be the recognition of those patients at higher risk of hyperinflammatory response to recognize hyper/hypo-inflammatory sub-phenotypes such as those currently under investigation in ARDS. This is matter of debate since HAPE is a poorly defined pathophysiological entity, hence not clearly supporting the use of this terminology and its implication for therapy to date (Sinha et al., 2020). A universal agreement on the use of corticosteroids in non-COVID ARDS is still lacking, but national guidelines started to consider the use of low-dose steroids in ARDS, while recommending against the use of high doses that may result in immune suppression and increased risk of opportunistic infections (Tasaka et al., 2022). COVID-19 has boosted the pharmacological research investigating the role of several immunomodulating agents in respiratory failure, including steroids, anti-interleukin monoclonal antibodies and drugs with indirect action on the immune response (Battaglini et al., 2022). While the use of steroids in hospitalized COVID-19 patients requiring oxygen supplementation is an established practice, these are typically contraindicated in initial, mild COVID-19. The use of other immunomodulating agents requires careful patient selection in COVID-19 and, more importantly, caution when translating to ARDS the findings of studies conducted in COVID-19 related respiratory failure (Battaglini et al., 2022).

6. Potential overlap of pathways involved

6.1. Renin-angiotensin system

The renin-angiotensin system (RAS) has been identified as potential effector in the pathophysiology of pulmonary diseases. Particularly, angiotensin II exerts multiple function for maintaining the homeostasis of blood pressure, vasoconstriction, and sodium balance. Angiotensin converting enzyme2 (ACE2) also plays an important role. In fact ACE deficit mice or the use of inhibitors led to remodeling of pulmonary arterioles (Kuba et al., 2006) and Deletion/Deletion (D/D) polymorphism of ACE gene was associated with more severity of pulmonary symptoms (Kuba et al., 2006). ACE inhibitors may attenuate endothelial dysfunction and fibrosis in interstitial pneumonia. Both clinical and experimental animal studies have implicated ACE in the pathogenesis of ARDS (Marshall et al., 2002; Raeden et al., 2002), suggesting its role in pulmonary vascular tone/permeability, epithelial cell survival, and fibroblast activation. D/D gene polymorphism again was more abundant in patients with ARDS than general ICU/ general population, and was associated with higher mortality (Marshall et al., 2002). Recombinant ACE2 protein improved the symptoms and fibrotic changes in ARDS,
playing a protective role (Kuba et al., 2006). Similarly, HAGE recognizes the role of ACE2 and RAS in the pathogenesis of increased arterial pulmonary pressure, as occurs in response to hypoxia (Kleinsasser et al., 2012). The importance of the RAS in lung diseases has recently re-emerged with the identification of ACE2 in SARS-CoV-2. SARS-CoV-2 enters lung cells via the ACE2 receptor. ACE2 receptors are recognized by macrophages and other pro-inflammatory cells, spreading to other organs and infecting ACE2-expressing cells at local sites, potentially causing multi-organ disease (Al-Kuraishy et al., 2020).

6.2. Neuropilin-1

Neuropilin-1 (NPN-1) is a cell surface receptor that binds vascular endothelial growth factor (VEGF), potentially influencing endothelial permeability, chemotaxis, and proliferation. Inhibition of NPN-1 revealed attenuation of VEGF-mediated permeability of pulmonary artery endothelial cells, probably regulating endothelial barrier dysfunction in response to VEGF (Becker et al., 2005). In patients with ARDS, VEGF receptors 1 and 2 are up-regulated, whereas NPN-1 is down-regulated in comparison with patients without ARDS (Medford et al., 2009). Some studies demonstrated that changes in the plasma level of VEGF and soluble VEGF receptor-1 as well as NPN-1 are associated with HAPE (Zhang et al., 2018). In COVID-19, NPN-1 protein interacts with the host cell receptor is the Spike-1 (S1) subunit of the coronavirus, thus favoring SARS-CoV-2 entry into the cells, and in particular to the central nervous system (Al-Kuraishy et al., 2021).

6.3. Hypoxia-inducible factor

Hypoxia-inducible factor (HIF) – 1 is a transcriptional activator dependent on oxygen, which plays an important role in maintaining oxygen homeostasis by regulating the expression of genes associated with adaptation to hypoxia. HIF-1 induces the release of inflammatory factors, thus exacerbating lung injury (Li et al., 2020). During hypoxic conditions, HIF-1 induces VEGF expression regulating pulmonary vascular permeability and promotes alveolar type II cells apoptosis. In the progression of ARDS, HIF-1 enhances glucose metabolism in epithelial cells, thus increasing lung ventilation and improving pulmonary edema and respiratory distress (Li et al., 2020). During normoxia, HIF-1α levels were recognized as markers of HAPE susceptibility (Soree et al., 2016). In COVID-19, HIF-1α promoted SARS-CoV-2 infection and aggravated inflammatory responses (Tian et al., 2021).

7. Future directions

COVID-19 may be complicated by the so-called post-COVID-19 syndrome which manifests with symptoms duration for more than 3 months and progressive pulmonary fibrosis (Meha et al., 2022). The pathogenesis of post-COVID-19 syndrome include direct tissue injury associated with autoimmunity antibodies. This new entity probably results from the interplay between epithelial and endothelial injury, immune-genetic susceptibility, ARDS, and/or ventilator-induced lung injury, hyperinflammation, and hypercoagulability, that in turn activate pro-fibrotic processes and a fibro-proliferative cascade. The impact of post-COVID-19 syndrome is currently unknown, as well as the influence of new COVID-19 variants, vaccination, ventilatory setting, immunomodulation and inflammation on it. The identification of COVID-19 phenotypes, as well as the understanding of physiological, radiological, and anatomopathological implications, and their evolution are paramount for progressing therapeutic targets and personalized medicine (Meha et al., 2022).

8. Conclusions

Remodeling and destruction of lung tissue may explain silent hypoxemia, intubation ineffectiveness, rapid progression to severe gasping, and finally, death in most COVID-19 patients. These processes are characterized by active viral replication of COVID-19 within type-2 pneumocytes associated with persistent infiltration of inflammatory cells, as well as a continuous repair process, but with an intense reactive fibrotic activity and superimposed opportunistic infections that finally lead to death. For this reason, extensive destruction of the lung parenchyma can be easily confounded with other diseases that may coexist in COVID-19 but can also help to explain the post-disease fibrosis, residual respiratory insufficiency, and exercise limitation.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Funding

None.

Competing interests

None.

Data availability

No data was used for the research described in the article.

Acknowledgments

We acknowledge the late Prof. Dr. Gustavo Zubieta-Castillo (Sr.), our mentor. We also thank Lucrecia DeUrioste and Rafaela Zubieta-DeUrioste for their collaboration and suggestions.

References

Ackermann, M., Verleden, S.E., Kuehnel, M., Huverich, A., Welte, T., Laenger, F., Vanstapel, A., Werlein, C., Stark, H., Tzankov, A., Li, W.W., Li, V.W., Mentzer, S.J., Jonigk, D., 2020. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 383, 120–128. https://doi.org/10.1056/NEJMoa2015432.

Al-Kuraishy, H.M., Al-Gareeb, A.I., Alzahrani, K.J., Cruz-Martins, N., Battha, G.E.S., 2021. The potential role of neopterin in Covid-19: a new perspective. Mol. Cell. Biochem. 476, 4161–4166. https://doi.org/10.1007/s11010-021-04232-z.

Al-Kuraishy, H.M., Hussein, N.R., Al-Naimi, M.S., Al-Ruaidly, A.K., Al-Gareeb, A.I., Lungnier, C., 2020. Renin–Angiotensin system and fibrinolytic pathway in COVID-19: One-way skepticism. Biomed. Biotechnol. Res. J. 4, 33–40. https://doi.org/10.4103/bbrj.bbrj.105.20.

Angeles Montero-Fernandez, M., Pardo-Garcia, R., 2021. Histopathology features of the lung in COVID-19 patients. Diagn. Histopathol. 27, 123–127. https://doi.org/10.1016/j.dhdp.2020.11.009.

Arias-Reyes, C., Zubieta-DeUrioste, N., Poma-Machicao, L., Aliaga-Raduan, F., Carvajal-Rodriguez, F., Dutschmann, M., Schneider-Gasser, E.M., Zubieta-Calleja, G., Soliz, J., 2020. Does the pathogenesis of SARS-CoV-2 virus decrease at high-altitude? Respir. Physiol. Neurobiol. 277, 103443. https://doi.org/10.1016/j.resp.2020.103443.

Ball, I., Barisione, E., Mazzotti, L., Campora, M., Costa, D., Robbo, C., Battaglini, D., Micali, M., Costantino, F., Citadinai, G., Patronini, N., Pelosi, F., Fiocca, R., Grillo, F.,
1. Acute respiratory distress syndrome (ARDS) is a form of acute lung injury characterized by the sudden onset of bilateral pulmonary edema resulting from increased vascular permeability. The pathogenesis of ARDS is multifactorial, involving both direct and indirect mechanisms.

2. In addition to direct lung injury, systemic inflammation and immune activation contribute to the development of ARDS. The cytokine storm hypothesis suggests that elevated levels of pro-inflammatory cytokines and chemokines lead to vascular leakage and tissue injury.

3. The role of genetic factors in the susceptibility to ARDS has been studied extensively. For example, polymorphisms in the angiotensin-converting enzyme (ACE) gene have been associated with an increased risk of ARDS.

4. The treatment of ARDS involves supportive care, respiratory therapy, and specific therapies targeting the underlying mechanisms. Oxygen therapy, mechanical ventilation, and prone positioning are commonly used interventions.

5. Clinical trials have shown that some therapeutic approaches, such as the use of inhaled nitric oxide and prone positioning, may improve outcomes in patients with ARDS.

6. Despite these advances, the mortality rate of ARDS remains high, with up to 50% of patients dying within 1 year of diagnosis. Therefore, continued research is needed to develop more effective treatments and preventions strategies.
Tallet, A., Anión, J.M., Fernández, R.L., González-Martín, J.M., Aguilar, G., Alba, F., Álvarez, J., Ambros, A., Anión, J.M., ASENSIO, M.J., Belda, J., Blanco, J., Blanco, M., Cachañero, I., del Campo, R., Capilla, I., Carbonell, J.A., Carbonell, N., Carrión, A., Carriero, D., Chico, M., Conesa, I.A., Corpas, R., Cazorla, J., DÍAZ-Domínguez, F.J., Domínguez-Anteo, C., Fernández, L., Fernández, R.L., Fernández, C., Ferreres, J., Gamboa, E., González-Higuera, E., González-Lizeng, R.I., González-Martín, J.M., Martínez, D., Martín-Rodríguez, C., Muñoz, T., Ortiz Díaz-Miguel, R., Pérez-González, R., Prieto, A.M., Prieto, I., Rivas, D., Rojas-Vigüera, L., Romero, M.A., Sánchez-Ballesteros, J., Segura, J.M., Serna-Granado, P., Serrano, A., Solano, R., Soler, J.A., Soro, M., Tallet, A., Villar, J., 2020. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir. Med 8, 267–276. https://doi.org/10.1016/S2213-2600(19)30417-5.

Wichmann, D., Sperhake, J.-P., Lütgehetmann, M., Steurer, S., Edler, C., Heinemann, A., Heinrich, F., Kniep, I., Schr¨oder, A.S., Burdere, M., Becker, H., Bredereke-Wiedling, H., de Weerth, A., Paschen, H.-R., ReichMaden, E., Stang, A., Schmiedel, S., Bokemeyer, C., Addo, M.M., Arpelbacher, M., Pischel, K., Kluge, S., 2020. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann. Intern. Med. 173, 268–277. https://doi.org/10.7326/M20-2003.

Wiersinga, W.J., Rhodes, A., Cheng, A.C., Peacock, S.J., Prescott, H.C., 2020. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19). JAMA 324, 782. https://doi.org/10.1001/jama.2020.12839.

Wilkins, M.R., Ghofrani, H.-A., Weissmann, N., Aldashev, A., Zhao, L., 2015. Pathophysiology and treatment of high-altitude pulmonary vascular disease. Circulation 131, 582–590. https://doi.org/10.1161/CIRCULATIONAHA.114.006977.

Xaubet, A., Ancochea, J., Bollo, E., Fernández-Fabrellas, E., Franquet, T., Molina-Molina, M., Montero, M.A., Serrano-Mollari, A., 2013. Guidelines for the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Arch. Bronconeumol. (Engl. Ed. 49, 343–353. https://doi.org/10.1016/j.arbr.2013.06.003.

Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., Tai, Y., Bai, C., Gao, T., Song, J., Xia, F., Dong, J., Zhao, J., Wang, F.-S., 2020. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 8, 420–422. https://doi.org/10.1016/S2213-2600(20)30076-X.

Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., Zhou, Q., 2020. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Sci. (80-. ) 367, 1444–1448. https://doi.org/10.1126/science.aab2762.

Zhang, S., Liu, J., Jiang, D., Wuren, T., Ma, S., Du, Y., Yi, X., Wu, S., 2018. The plasma level changes of VEGF and soluble VEGF receptor-1 are associated with high-altitude pulmonary edema. J. Med. Invest 65, 64–68. https://doi.org/10.2152/jmi.65.64.

Zubieta-Calleja, G., 1989, High Altitude Pathology at 12000 Ft. Zubieta-Calleja, G., Zubieta-DeUrioste, N., 2021a. The oxygen transport triad in high-altitude pulmonary edema: a perspective from the high andes. Int. J. Environ. Res. Public Health 18, 7619. https://doi.org/10.3390/IJERPH18147619.

Zubieta-Calleja, G., Zubieta-DeUrioste, N., 2021b. Pneumolysis and “Silent Hypoxemia” in COVID-19. Indian J. Clin. Biochem. 36, 112–116. https://doi.org/10.1007/s12291-020-00935-0.

Zubieta-Calleja, G., Ardaya, G., Zubieta-DeUrioste, N., Paulev, P., Zubieta-Castillo, G., 2013, Tolerance to hypoxia [WWW Document]. zuniv.net. URL 〈https://zuniv.net/pub/TolerancetoHypoxiaFiziol.pdf〉.

Zubieta-Calleja, G., Zubieta-DeUrioste, N., Venkatesh, T., Das, K.K., Soliz, J., 2021. COVID-19 and Pneumolysis Simulating Extreme High-altitude Exposure with Altered Oxygen Transport Physiology; Multiple Diseases, and Scarcity Need of Ventilators: Andean Condor’s-eye-view. Rev. Recent Clin. Trials 15, 347–359. https://doi.org/10.2174/1574887115666200325141108.

Zubieta-Calleja, G.R., Zubieta-DeUrioste, N., 2022. High Altitude Pulmonary Edema, High Altitude Cerebral Edema, and Acute Mountain Sickness: an enhanced opinion from the High Andes – La Paz, Bolivia 3,500 m. Rev. Environ. Health. https://doi.org/10.1515/reveh-2021-0172.